Neuropathy progression in hereditary transthyretin amyloidosis (ATTRv) patients after liver transplantation

Catarina Falcão de Camposa Instituto de Fisiologia, Instituto de Medicina Molecular, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal;b Department of Neurosciences and Mental Health, Centro Hospitalar Universitário de Lisboa-Norte, Lisbon, PortugalCorrespondence[email protected]
View further author information

Isabel Conceiçãoa Instituto de Fisiologia, Instituto de Medicina Molecular, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal;b Department of Neurosciences and Mental Health, Centro Hospitalar Universitário de Lisboa-Norte, Lisbon, Portugal

https://orcid.org/0000-0003-0934-9631 View further author information

References

Adams D, Koike H, Slama M, et al. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387–404. doi: 10.1038/s41582-019-0210-4.
PubMed Web of Science ®Google Scholar
Ericzon B, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99(9):1847–1854. doi: 10.1097/TP.0000000000000574.
PubMed Web of Science ®Google Scholar
Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010;75(4):324–327. doi: 10.1212/WNL.0b013e3181ea15d4.
PubMed Web of Science ®Google Scholar
Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J Intern Med. 2017;281(4):337–347. doi: 10.1111/joim.12585.
PubMed Web of Science ®Google Scholar
Schmidt HH, Wixner J, Planté-Bordeneuve V, Patisiran Post-LT Study Group, et al. Patisiran treatment in patients with transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. Am J Transplant. 2022;22(6):1646–1657. doi: 10.1111/ajt.17009.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Neuropathy progression in hereditary transthyretin amyloidosis (ATTRv) patients after liver transplantation

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Neuropathy progression in hereditary transthyretin amyloidosis (ATTRv) patients after liver transplantation

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date